Navigation Links
Synvista Therapeutics Posts Letter to Stockholders on Web Site
Date:9/17/2008

having successfully directed development and registration programs in various therapeutic areas, including cardiovascular and metabolic diseases, dermatology, gastroenterology and immunology.

We are very excited about the role Synvista has to play in fulfilling important, unmet medical needs in diabetic and other patients as we advance our pipeline through development and into commercialization.

Thank you for your continued interest in Synvista. I look forward to keeping you apprised of our progress.

Sincerely,

Noah Berkowitz, M.D., Ph.D.

President and Chief Executive Officer

September 2008

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing diagnostics and drugs to diagnose, treat and prevent cardiovascular disease in people with diabetes. The Company has developed a clinical diagnostic test for Hp2-2 Diabetes. The genetic or protein form of this test can be used to identify diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker.

Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 Diabetes, a disease affecting almost 7 million patients in the United States. The Company is also developing alagebrium, a proposed breaker of advanced glycation endproducts (AGEs) for the treatment of systolic and diastolic heart failure. Diastolic heart failure represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
2. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
3. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
4. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
5. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
6. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
7. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
8. Synvista Therapeutics to be Featured on Wallst.net
9. Synvista Therapeutics to Present at the BIO InvestorForum 2007
10. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015 E-QURE Corp. (OTCQB: ... its Bio-electrical Signal Therapy device ("BST Device"), a new ... to heal chronic wounds, today announced that the Company ... Israeli distributor specializing in medical devices, for the marketing ... is a 70 years old, sales, marketing and distribution ...
(Date:8/3/2015)... NEW YORK , August 3, 2015 ... "Global Market Study on 3D Cell Culture: ... published by Persistence Market Research, the global 3D cell culture ... is expected to expand at a CAGR of 29.1% ... View Full Report with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... vacuum pumps to its comprehensive line of analytical laboratory equipment. With optimized features, ... versatile pumps provide a chemically resistant and maintenance-free solution for a broad range ...
(Date:7/31/2015)... ... 31, 2015 , ... Global Resorcinol Market 2015-2019 is a ... the global resorcinol industry. The report highlights the various growth prospects and the ... analysis of primary and secondary inputs from the existing players of the resorcinol ...
Breaking Biology Technology:E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4Sterlitech Launches New Line of Vacuum Pumps 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4
... San Francisco, CA, March 18, 2011 Cytokinetics, Incorporated ... in the March 18, 2011 issue of the journal ... by an investigational drug candidate, omecamtiv mecarbil, and the ... for patients with systolic heart failure. This publication ...
... Quest Diagnostics Incorporated (NYSE: DGX ), ... its ColoVantage test has been approved by New York ... in the state. It is believed to be the ... blood specimen to be approved by the state.   ...
... Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS ... and webcast discussing the Company,s 2010 fourth quarter and full-year ... (EDT). Michael T. Flavin, Ph.D., Chairman & Chief Executive Officer, ... also present an update on the Company. A press release ...
Cached Biology Technology:Cytokinetics announces fundamental research in cardiac myosin activation in the journal Science 2Cytokinetics announces fundamental research in cardiac myosin activation in the journal Science 3New York State Approves the Quest Diagnostics ColoVantage™ Colorectal Cancer Blood Test 2New York State Approves the Quest Diagnostics ColoVantage™ Colorectal Cancer Blood Test 3Advanced Life Sciences to Host 2010 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast 2
(Date:7/21/2015)... OXFORD, Connecticut , July 21, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... the Wocket® smart wallet, announces that it has ... Tokenization System and Method. This ... that not only authorizes an account, but also ...
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015  Synaptics ... interface solutions, announced today that it will report financial ... on Thursday, July 30, 2015 after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... Despite research efforts to find modern factors that would ... the gap is actually ancient and universal, according to ... almost every country, and the sex difference in lifespan ... said Daniel J. Kruger, a research scientist in the ...
... small, inexpensive remote-control plane as a sensing tool, also known ... team plans to test it over the Konza Prairie Biological ... performs as the team hopes, it will be made available ... it to obtain high-resolution images and reliable data. , The ...
... has been developed, which quite literally sucks the life ... place ozone-depleting chemicals, like methyl bromide, which are currently ... called metabolic stress disinfection (MSDD), was developed by Manuel ... (Journal of the Science of Food and Agriculture DOI ...
Cached Biology News:Evolutionary forces explain why women live longer than men 2K-Staters design and build a low-cost remote sensing tool for environmental studies 2K-Staters design and build a low-cost remote sensing tool for environmental studies 3
Rabbit polyclonal to SMARCA2 / BRM - ChIP Grade ( Abpromise for all tested applications). entrezGeneID: 6595 SwissProtID: P51531...
Determin interaction of your protein with Echelons lipids...
Mouse monoclonal [CAT-2] to Chloramphenicol Acetyltransferase...
Anti-Human Complement Component C4c, IgY fraction (Polyclonal) (chicken IgY)...
Biology Products: